High-sensitivity AFP-L3%, with a sensitivity of 41.5% and a specificity of 85.1% for the diagnosis of AFP-negative HCC, and its combination with PIVKA-II can effectively improve the diagnostic value of AFP-negative HCC, and in the AFP-negative HCC group, the positive rate of these markers combined to detect early HCC was 81.8%, that to detect small HCC was 86.7%, and that to detect single tumors was 91.7% (15, 16). The gene discussed is AFP; the disease is hepatocellular carcinoma.